Chemo, Immunotherapy, and Heated Belly Chemo for Stomach Cancer Spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach cancer that has spread to the lining of your belly (called the peritoneum), but the spread is not too extensive.
- You have not had chemotherapy, radiation, targeted therapy, or immunotherapy before.
- You do not have other cancers, active autoimmune diseases, or serious heart/lung conditions.
- Your organs (kidneys, liver, blood cells) are working well enough, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination treatment for stomach cancer that has spread to the lining of the abdomen. It uses a special way to deliver heated chemotherapy directly into the abdomen, along with an immunotherapy drug that helps your immune system attack the cancer.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This study looks at samples of blood and tissue from people with advanced stomach cancer that has spread to the belly lining. The goal is to find markers that predict how well a treatment combining HIPEC (heated chemotherapy in the belly) with immunotherapy (drugs that help your immune system fight cancer) works.
This trial tests whether adding heated chemotherapy to the belly right after surgery can help people with stomach cancer live longer. It is done during the same operation, aiming to kill any remaining cancer cells.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.